Biosimilar Adoption Is Saving Employers 40–70% on Biologics: Where the Best Alternatives Are Right Now

When $34,000 per Year per Member Isn’t Inevitable: Humira, Biosimilars, and Real-World Results

I recently worked with a 700-life self-funded company staring down $460,000 a year in Humira prescriptions across just 12 members. Their pharmacy benefit manager contract looked solid at first glance, standard rebates, competitive admin fees, brand/generic mix in line with benchmarks. But when we ran the numbers, over 33% of their total pharmacy spend was tied up in a single molecule: adalimumab. Even with a generic dispensing rate of 91.3%, specialty was eating their budget alive. The CFO’s question was simple: “Is there anything we can actually do about this, or is it just the cost of playing in the big leagues?”

That’s where biosimilars go from industry buzzword to real-world budget rescue. For adalimumab (the reference brand is Humira), new biosimilar entrants like Hadlima, Hyrimoz, and Cyltezo are being priced to move, with discounts ranging from 50% to 70% off the sticker price of Humira. In the above scenario, moving even half the Humira utilization to a biosimilar could cut that $460,000 liability by up to $160,000 annually. That’s not rebate math or delayed hope; those are immediate invoice savings.

Some benefits managers worry biosimilars are just a specialty version of generics, good in theory, tough in practice. The industry has finally turned the corner. Adoption barriers aren’t fully gone, but in 2024, real alternatives exist in several high-impact drug classes.

Where Biosimilar Alternatives Are Delivering Deepest Savings

High-impact savings don’t happen in every specialty category, but the dominoes started falling with anti-TNF therapies like adalimumab and etanercept (Enbrel). Today, employers are seeing the biggest wins in:

• Rheumatology and Immunology: Humira biosimilars are now covered on nearly every PBM formulary, with some plans seeing 60-70% discounts versus the branded reference. For employers with even a handful of rheumatoid arthritis or Crohn’s disease members, the annual per-patient cost drop can reach $20,000 or more.
• Oncology Supportive Care: Filgrastim (Neupogen) and pegfilgrastim (Neulasta) biosimilars are well-established, often delivering 40-50% savings for cancer patients requiring neutropenia prophylaxis. These drugs aren’t as pervasive as Humira but add up quickly in larger populations.
• Insulins: While not technically biosimilars under FDA rules, “follow-on” insulins like Basaglar (vs Lantus) and Semglee are now widely substituted, typically saving 20-40%. The commercial market is seeing $35/month insulin copay caps, and authorized generics like insulin lispro (the Humalog authorized generic) are further pushing down spend in diabetes populations.
• Ophthalmology: Biosimilars for ranibizumab (Lucentis) and aflibercept (Eylea) are just starting to gain traction. The potential is there, these injectables can easily cost $10,000-$20,000 per year for a single retinal patient.

One employer I worked with, a 2,500-employee school district, moved all adalimumab claims to biosimilars (Hadlima) starting Q1 2024. Their pharmacy spend is now running $130,000 lower for the year, despite no change in total specialty utilization. Specialty drugs still account for 53% of their pharmacy spend, but for the first time in years, their PMPM dropped below $120. You can track these trends in live claims data and industry forecasts at RxPBM.ai.

Formulary Management: How to Actually Capture the Biosimilar Savings

You won’t see these savings unless your PBM’s formulary and prior authorization policies are set for biosimilar adoption. Many legacy PBM contracts default to the branded reference drug (especially with heavy rebates at stake). Without aggressive formulary moves, biosimilars often become second-line therapies, “available,” but rarely dispensed. Employers trying to capture invoice-level savings need to:

First, review your current formulary tiering and exclusions. Are biosimilars listed as preferred, or does the PBM still prefer the reference drug due to rebate guarantees? In some cases, you’ll need to push for exclusion of the reference brand (Humira, Enbrel, Neulasta) or step therapy that strongly favors biosimilars. PBMs like Capital Rx and Navitus are more likely to push biosimilars to the top tier, while the Big Three (CVS Caremark, Express Scripts/Cigna, OptumRx/UnitedHealth) vary by client and region. It pays to get this in writing during your annual PBM renewal or RFP cycle.

Second, look at member disruption. The best savings come from switching current reference drug users, not just new starts. When Humira biosimilars launched, many plans only applied new start policies. That leaves 90% of spend in the old channel. To move existing members, you’ll need clear communication, physician outreach, and sometimes a transition fill. In my experience, the disruption is lower than many HR teams fear, biosimilars are FDA-approved as “interchangeable” in some cases, and most prescribers are comfortable making the switch when properly educated.

Finally, monitor rebate guarantees. Some PBMs will offer sky-high specialty rebate numbers to keep the reference drug on formulary. These rebates don’t always offset the higher invoice cost of branded biologics. Always run the net cost math, ideally using real claims or data tools like RxInfo.ai, before you accept a rebate-driven strategy over biosimilars.

Where the Best Biosimilar Opportunities Are, And Where Gaps Remain

The biosimilar wave keeps building, but not all therapeutic areas are ready for aggressive adoption. Besides the established wins in rheumatology, oncology supportive care, and insulins, here’s what benefits managers should keep an eye on:

The next big class is infliximab (Remicade and biosimilars like Inflectra, Renflexis), used in autoimmune disorders. Uptake is growing, though some physicians still hesitate to switch stable patients. Oncology itself will see more biosimilar impact as complex monoclonal antibodies (trastuzumab/Herceptin, rituximab/Rituxan) lose patent protection. Savings can be dramatic, but adoption depends on your population and provider relationships.

Where are gaps? Asthma and allergy biologics (dupilumab/Dupixent, omalizumab/Xolair) aren’t facing real biosimilar competition yet. Multiple sclerosis (ocrelizumab/Ocrevus) and rare disease biologics remain high-cost, reference-only categories for now. GLP-1s (semaglutide/Ozempic, tirzepatide/Mounjaro) are all small-molecule or peptide drugs, not biologics, so biosimilars don’t apply. Employers will need separate strategies, copay solutions, utilization management, targeted exclusions, to address these.

For HR and finance leaders, the lesson is clear. Ask your PBM, or your pharmacy benefits consultant, to show you the exact classes where biosimilars can move the needle right now. Don’t settle for “biosimilars are available”, demand detail. And if your plan has a handful of Humira or Neulasta claims, run the numbers on a biosimilar-first approach. Even a single member switch can save $15,000-$30,000 a year, dwarfing most generic step therapy programs.

If you want to stay current on biosimilar launches and formulary changes, I recommend following regulatory and pipeline updates at RxNews.ai. For clinical differences between biosimilars and reference drugs, ClinicalRx.ai is a practical, plain-English resource for your employee comms.